INTRODUCTION

End-stage liver disease carries high mortality and morbidity, with liver transplantation being the only form of definitive treatment. In Singapore, despite state laws for mandatory organ donation and efforts to improve national awareness, the availability of liver grafts remains low. Based on statistics released by the Ministry of Health, Singapore, the number of patients on the national liver transplant waiting list tripled over a five-year period between 2007 and 2012, with an average of seven waiting-list patient deaths each year.¹

Graft availability is a common issue worldwide. In view of this, novel approaches to expand the graft supply have been experimented on and redefined over the years. One strategy involves the use of ‘marginal’ grafts from donors who have antibodies against hepatitis B virus core protein (anti-HBc) but test negative for hepatitis B surface antigen (HBsAg). These are commonly referred to as hepatitis B ‘core positive donors’. This is of clinical relevance, especially in Asia-Pacific countries like Singapore, where hepatitis B virus (HBV) infection remains endemic and the local anti-HBc positive rate is 22.5%.²

This article aims to: (a) review the HBV life cycle and the role(s) of covalently closed circular DNA (cccDNA) to improve understanding of the differences between anti-HBc positivity and occult HBV infection (OBI); and (b) highlight key points to ensure the safe utilisation of liver grafts from core positive donors and minimise the risk of de novo HBV infection (DNHI).

OVERVIEW OF HBV LIFE CYCLE

Structure of hepatitis B virion or ‘Dane particles’

Infectious virions (Fig. 1) comprise an outer envelope (i.e. hepatitis B envelope antigen, HBeAg) onto which surface proteins (i.e. HBsAg) are embedded. This encases an inner nucleocapsid ‘core’, where the viral genome exists in a partially double-stranded, circular configuration, without the typical covalent bonds between the positive (+) and negative (−) strands. This is commonly termed incomplete ‘relaxed circular’ DNA.

HBV replicative life cycle

HBV attaches to and gains entry into host cells (i.e. hepatocytes) through interactions between HBsAg and cellular surface receptors – sodium/taurocholate co-transporting polypeptide.⁴ The outer envelope is shed as the nucleocapsid core gains entry into the cytoplasm, while the nucleocapside core is shed as the HBV DNA is transported into the host cell nucleus. Within the

Fig. 1 (a) Electron micrograph shows the circulating forms of hepatitis B virion and subviral particles in blood, with a size range of 22‒42 nm. (b) Schematic diagram shows the structure of the hepatitis B virus (reproduced with permission of Wiley and Sons from Liang TJ). HBeAg: hepatitis B core antigen; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; Pol: polymerase; RT: reverse transcriptase
nucleus, the HBV genome first undergoes repair and structural changes catalysed by host DNA polymerase. This involves the addition of complementary nucleotides to the incomplete DNA strand and the creation of covalent bonds between the positive and negative DNA strands, with the end product being a complete cccDNA.

The cccDNA then serves as a functional template for the formation of translational RNA (coding for viral proteins), as well as pre-genomic RNA (an anti-sense ‘mirror’ from which additional copies of relaxed circular DNA are formed). Viral subunits and relaxed circular DNA subsequently undergo packaging to form new HBV virions, which are then released into the bloodstream, infecting other hepatocytes and perpetuating the HBV infection (see Fig. 2 for graphical illustration).

The role of antibodies to HBV envelope protein (anti-HBe) is not clear. The appearance of this antibody may not be initially detected by serological assays because it exists as antigen-antibody complexes with HBeAg. The latter is produced in extremely high quantities and ‘overwhelms’ the anti-HBe. The appearance of anti-HBe and disappearance of HBeAg are hence related to a decreased production of viral proteins and are indirect markers of the transition from an active HBV replicative state to a quiescent, low replicative state. This is confirmed by a low or undetectable HBV DNA level.

Similar to anti-HBe, antibodies to the nucleocapsid core (i.e. anti-HBc) are ‘non-neutralising’ antibodies that do not confer immune protection. Anti-HBc can be detected early in the course of HBV infection and typically persists lifelong. Given this characteristic, it is commonly regarded as a ‘serological scar’ (i.e. evidence of previous HBV exposure). In contrast, antibodies against HBsAg (anti-HBs) neutralise virions by inhibiting their ability to gain entry into host cells, thus preventing HBV infection. Individuals who achieve anti-HBs seroconversion following HBV infection will typically have no detectable HBV DNA in the serum. The expected sequence of appearance of serologic markers in acute and chronic HBV infection is depicted in Fig. 3.

**HBV SEROLOGY**

HBV is able to escape host immune detection through a series of mechanisms that cause chronic infection. This will not be covered here, as it is beyond the scope of the article. Notwithstanding this, antigenic stimuli exerted by circulating virions will eventually trigger a response from the host’s adaptive immune system, resulting in the production of antibodies against the viral proteins.
OCCULT HBV INFECTION

HBV nuclear cccDNA molecules have a chromatin-like structure and can exist within the nucleus as a stable viral minichromosome. The transcriptional, and thus replicative, activity of HBV cccDNA is dependent on poorly understood interactions between ‘activating factors’ (such as the HBV X protein) and epigenetic control by the host cell. This is part of the virological key that explains the continued persistence of HBV.

Therefore, those who have had previous HBV infection (i.e. anti-HBc positive) with a reservoir of HBV cccDNA within the hepatocytes run a perpetual risk of viral reactivation despite anti-HBs seroconversion and HBV DNA clearance from the serum. Such persons are deemed to have OBI; i.e. detectable HBV DNA in the liver (cccDNA in this case) of HBsAg-negative individuals regardless of serum HBV DNA and anti-HBs status.

Patients with OBI should not be confused with those harbouring HBV ‘S escape mutants’, as the latter typically have modified HBsAg that is not recognised by commercially available detection assays. In addition, they would have positive anti-HBc and falsely negative HBsAg results. However, the most obvious distinguishing feature is the typically high serum HBV DNA level, which is comparable to that seen in patients with chronic HBV infection.

Natural history of patients with OBI

Little is known about the natural history of patients with OBI. Chemin et al retrospectively reviewed the serum HBV DNA level of 26 patients with cryptogenic hepatitis who were negative for HBsAg and positive for anti-HBc antibodies. Over the period of follow-up, all had transient episodes of HBV DNA positivity, albeit at low titres < 1 × 10^6 copies/mL. There was no relationship between alanine transaminase levels and HBV DNA detectability.

Prevalence of OBI among anti-HBc positive patients

Some authors have attempted to confirm the presence of OBI by measuring the HBV DNA level in patients with positive anti-HBc, and found a frequency of HBV DNA seropositivity of 0.56%–8.00%. In a similar attempt, Tandoi et al analysed the liver tissue of patients who were negative for HBsAg and positive for anti-HBc, and found that up to 60% of patients had detectable cccDNA. In this cohort, serum HBV DNA was positive in only 17% of patients with detectable cccDNA. At present, the turnover kinetics of HBV cccDNA remains unclear. However, viral reactivation can occur even among those with resolved HBV infection in the previous decades, reflecting the extremely slow rate of clearance of HBV cccDNA.

ANTI-HBC DONORS: A POTENTIAL SOURCE OF DE NOVO HBV INFECTION?

In the context of immunosuppression, intermittent increases in HBV cccDNA transcriptional activity and release of hepatitis B virions into the bloodstream may not be effectively contained by a weakened immune system. In view of this, the transplantation of liver grafts from donors with OBI poses a potential risk of DNHI to the recipients, due to the near-universal use of immunosuppressive medications to prevent graft rejection. Intuitively, the ideal approach would be to further risk stratify the cohort with positive anti-HBc antibodies, so as to identify and exclude those with OBI from organ donation, thus eliminating the risk of cross infection. Unfortunately, to assess liver tissue for cccDNA mandates a liver biopsy, and expertise required is neither cheap nor easily available.

A systematic review conducted by Cholongitas et al on recipients receiving liver grafts with positive anti-HBc concluded that the risk of DNHI is highest among recipients who are naïve to HBV infection (47.8%). Their findings on recipients who did not receive post-transplant prophylaxis are summarised in Fig. 4. This is supported by Skagen et al, who showed a rate of DNHI of 58% in HBV-naïve liver transplant recipients. The fact that the risk of DNHI in HBV-naïve recipients so closely mirrors the prevalence of OBI among patients with positive anti-HBc antibodies suggests that DNHI may be an inevitable event in such circumstances.
contrast, recipients who had acquired natural immunity were at the lowest risk of DNHI (1.4%–4.0%). Patients who were anti-HBc positive/anti-HBs negative or anti-HBc negative/anti-HBs positive demonstrated intermediate risks of DNHI of 9.7%–18.0%.

(20,21) PRACTICAL MANAGEMENT OF ANTI-HBC DONORS AND DNHI RISK

Patients with natural immunity do not require immunoprophylaxis due to the low rates of DNHI and can be followed up with serial measurement of HBV DNA levels. Immunoprophylaxis should be considered in other groups of patients due to their significant risks of DNHI.

Three main strategies have been used to reduce the risk of DNHI: (a) hepatitis B immunoglobulin (HBIG); (b) nucleoside analogues (mainly lamivudine); and (c) a combination of the two. HBIG monotherapy has only been shown to have marginal benefits in preventing DNHI and thus should not be used as such. (20,21) The risk of DNHI was reduced from 9.7%–18.0% to 0%–4% with the use of lamivudine with or without HBIG immunoprophylaxis. (20,21) In a separate systematic review, Saab et al demonstrated that combination therapy of HBIG and lamivudine (4/110, 3.6%) did not result in better risk reduction of DNHI, as compared to lamivudine monotherapy (2/73, 2.7%). (22) The American and Canadian Societies of Transplantation have jointly published a set of consensus guidelines for the post-transplant management of patients receiving solid organs from anti-HBc positive donors. (23) A summary of the guidelines is shown in Fig. 5.

Lamivudine is the most extensively evaluated nucleoside analogue and is recommended as the most cost-effective option for reducing the risk of DNHI. Antiviral resistance, typically a concern with long-term lamivudine therapy, is less commonly encountered in the context of post-transplant prophylaxis; this is likely related to the fact that cccDNA exists in the low replicative state and HBV DNA titres (if at all detected in the serum) tend to be low. (24) Despite this, newer nucleoside analogues with high genetic barrier to resistance are increasingly being used today. Although large-scale clinical data and information on the long-term cost-effectiveness of entecavir and tenofovir are still lacking, their use in this context has been associated with favourable results in preventing DNHI. (25)

CONCLUSION

In conclusion, there is a high prevalence of OBI among individuals with anti-HBc antibodies. Nevertheless, liver grafts from these patients can be safely utilised if appropriate recipient matching and adequate post-transplant prophylaxis are performed. The ideal prophylactic regime for the prevention of DNHI is not clearly defined due to the lack of robust data and varied practice across different institutions. Although there seems to be a paradigm shift from long-term immunoprophylaxis to nucleoside analogue monotherapy without immunoprophylaxis, this requires further validation.
REFERENCES

2. Ang LW, Cutter J, James L, Goh KT. Seroprevalence of hepatitis B virus infection
3. Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with
4. Nguyen DH, Ludgate L, Hu J. Hepatitis B virus-cell interactions and
5. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical
6. Tuttleman JS, Pourseil J, Summers J. Formation of the pool of covalently closed
13:48-64.
50:S61-7.
11. Skagen CL, Jou JH, Said A. Risk of de novo hepatitis in liver recipients from
hepatitis-B core antibody-positive grafts - a systematic analysis. Clin Transplant
12. Saab S, Waterman B, Chi AC, Tong MJ. Comparison of different
immunoprophylaxis regimens after liver transplantation with hepatitis B core
hepatitis B core antibody-positive livers: consensus guidelines for recipient